MUMBAI, India–(BUSINESS WIRE)–ICICI Bank Limited (NYSE: IBN) filed its annual report in Form 20-F for the year ended March 31, 2022 (FY2022) on July 29, 2022, as required by United States securities regulations. The Form 20-F annual report includes the Bank�s consolidated financial statements under Indian GAAP and a reconciliation of consolidated profit after tax and net worth under Indian GAAP to net income and stockholders equity under U.S. GAAP, approved by the Audit Committee of the Board.
Copies of the Form 20-F are available from the United States Securities and Exchange Commission (SEC) website www.sec.gov or via a direct link to the SEC website at “About Us/Investor Relations/SEC Filings” page of ICICI Bank’s website:
https://www.sec.gov/Archives/edgar/data/1103838/000095010322013302/dp173855_20f.htm
Shareholders may obtain a copy of the complete audited financial statements free of charge by writing to General Manager & Company Secretary, ICICI Bank Limited, ICICI Bank Towers, Bandra Kurla Complex, Mumbai 400051 or sending an e-mail to companysecretary@icicibank.com, with details of their shareholding and mailing address.
Contacts
For further press queries please call Sujit Ganguli / Kausik Datta at 91-22-2653 8525 / 91-22-2653 7026 or e-mail at corporate.communications@icicibank.com.
For investor queries please call Abhinek Bhargava / Aashwij Mallya at 91-22-24008 6173 / 91-22-4008 7107 or email at ir@icicibank.com.
DUBLIN--(BUSINESS WIRE)--The "Thailand Existing & Upcoming Data Center Portfolio" report has been added to ResearchAndMarkets.com's…
AI-innovation leader recognized for driving transformative change in cybersecurity, setting new standard for ecosystem excellence…
BANGKOK, THAILAND - Media OutReach Newswire - 27 November 2024 - SM Investments Corporation ("SM…
JAKARTA, INDONESIA - Media OutReach Newswire - 27 November 2024 - Live Nation, TEM Presents,…
HAI PHONG, VIETNAM - Media OutReach Newswire - 26 November 2024 - November 26, 2024,…
NEW YORK, US - Media OutReach Newswire - 26 November 2024 - From pharmaceutical manufacturing…